Below are brief introductions to dengue disease and the dengue vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.
Dengue illness is caused by an infection with the dengue virus, a flavivirus, that is transmitted by the Aedes aegypti and the Aedes albopictus mosquitoes, two types of mosquitoes found in subtropic and tropic regions of the world.1
There are four dengue serotypes (Type 1, 2, 3, and 4), and infection with one of the dengue viruses will provide a person with long-term immunity from that specific virus. It is possible to become infected with dengue more than once since there are four distinct types of dengue viruses.2
The U.S. Food and Drug Administration (FDA) has approved DENGVAXIA, a live dengue tetravalent vaccine targeting dengue serotypes 1, 2, 3, and 4 for use in children and adolescents aged six through 16 years with a laboratory confirmed history of previous dengue infection and living in dengue endemic area.3 The U.S. Center for Disease Control and Prevention (CDC) recommends DENGVAXIA vaccine for use in children aged nine through 16 years with a laboratory confirmed history of past dengue infection and who live in dengue endemic U.S. Territories and Freely Associated States.4
DENGVAXIA is not approved for individuals who have no prior history of dengue infection or where the history of previous infection is not known. Individuals with no prior history of dengue are at an increased risk of developing severe dengue infection should they receive this vaccine and become infected with the dengue virus.5
Below are brief introductions to dengue disease and the dengue vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.
Dengue illness is caused by an infection with the dengue virus, a flavivirus, that is transmitted by the Aedes aegypti and the Aedes albopictus mosquitoes, two types of mosquitoes found in subtropic and tropic regions of the world.1
There are four dengue serotypes (Type 1, 2, 3, and 4), and infection with one of the dengue viruses will provide a person with long-term immunity from that specific virus. It is possible to become infected with dengue more than once since there are four distinct types of dengue viruses.2 Learn more about dengue…
The U.S. Food and Drug Administration (FDA) has approved DENGVAXIA, a live dengue tetravalent vaccine targeting dengue serotypes 1, 2, 3, and 4 for use in children and adolescents aged six through 16 years with a laboratory confirmed history of previous dengue infection and living in dengue endemic area.3 The U.S. Center for Disease Control and Prevention (CDC) recommends DENGVAXIA vaccine for use in children aged nine through 16 years with a laboratory confirmed history of past dengue infection and who live in dengue endemic U.S. Territories and Freely Associated States.4
DENGVAXIA is not approved for individuals who have no prior history of dengue infection or where the history of previous infection is not known. Individuals with no prior history of dengue are at an increased risk of developing severe dengue infection should they receive this vaccine and become infected with the dengue virus.5 Learn more about dengue vaccine…